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Purpose. Assessment of eﬀects of zoledronic acid therapy on bone metabolic indicators in hormone-resistant prostate cancer
patients with bone metastasis. Material and Methods. Hormone-resistant prostate cancer patients who were identiﬁed to have
metastases in their bone scintigraphy were taken to trial group. Before administration of zoledronic acid, routine tests for serum
calcium, total alkalen phosphates were studied. Sample sera for bone metabolic indicators BALP, PINP, and ICTP were collected.
Bone pain was assessed via visual analogue scale and performance via Karnofsky performance scale. Four mg zoledronic acid was
administered intravenously once a month. Results. When serum levels of bone forming indicators PINP; BALP were compared
before and after therapy, there were insigniﬁcant decreases (P = .33, P = .21, resp.). Serum levels of bone destruction indicator
ICTP was compared, and there was a signiﬁcant decrease after zoledronic acid therapy (P = .04). When performances of the
patients were compared during therapy period, performances decreased signiﬁcantly due to progress of illness (P = .01). All
patients had ostalgia caused by bone metastases at various degrees. Signiﬁcant decrease in pain scores was observed (P<. 01).
Conclusion. Zoledronic acid therapy decreased bone destruction and was eﬀective in palliation of pain in patient with bone
metastasis.Using bone metabolic indicators during followup of zoledronic acid therapy might be useful.
1.Introduction
Prostate canceristhe fourth most common male malignancy
in the world and the ﬁrst in North America [1]. Treatment
fortheillnessshouldbeplannedinaccordancewiththestage,
age,lifeexpectance,andadditionalillnesses. Theﬁrsttherapy
in patients with acute stage prostate cancer is to decrease
androgens via medical or surgical castration. However, in
most of the cases the illness progresses throughout this
therapy. Average life span of the hormone-resistant prostate
cancer patients is about eighteen months and no contri-
bution to the life span through extra therapies could be
demonstrated [2].
In prostate cancer potential of bone metastases is high.
Bone lesions seen in prostate cancer are of osteoblastic
characteristic, and they make extreme bone reconstruction
and destruction around metastatic areas [3]. Therefore local
osteopenia and widespread bone metabolism disorders are
seen in patients with advanced stage prostate cancer.
Traditional approach in the treatment of bone metastatic
patients is the application of supportive or palliative
therapies besides standard anticancer therapy [4]. Serious
ostalgia may be cured with radiotherapy or radio-nuclides
and many patients also take systemic analgesic therapy via
nonsteroidal anti-inﬂammatory medicines or opioids.
Recently, bisphosphonate therapy has become highly
eﬃcient alternative in preventing secondary skeletal compli-
cations in bone metastases [4]. Bisphosphonates both join in
active bone metabolism and especially adhere to bone. Dur-
ing bone degeneration they are released from bone matrix
and theypotentially decrease osteoclastactivity and life span.
Thus bone degeneration decreases [5]. Bisphosphonates are2 ISRN Urology
used to decrease skeletal complications, palliate pain and
prevent metastatic bone disorders [6].
We aimed at assessment of eﬀects of zoledronic acid
therapy on bone metabolic indicators in hormone-resistant
prostate cancer patients with bone metastasis.
2.MaterialandMethods
Patients receiving therapy were identiﬁed to have metastases
in their bone scintigraphy and resistant to hormone therapy
were taken to the trial group regardless of the number of
metastases. Before the initiation of zoledronic acid therapy,
routine tests prostate-speciﬁc antigen (PSA), serum calcium
(Ca),andtotalalkalinephosphates(TALP)werestudied.The
sample sera for bone metabolic indicators that bone-speciﬁc
alkaline phosphates (BALP), aminoterminal propeptide of
type I procollagen (PINP), carboxyterminal pyridinoline
cross-linked telopeptide of type I collagen (ICTP) were kept
at −70◦C.
According to the individual positions of the patients
radiotherapy for vertebral metastases, nonsteroid anti-
inﬂammatory medicines and opioidsfor pain palliation were
additionally given.
The degree of bone pain was assessed via visual analogue
scale (VAS) and their performances via Karnofsky perfor-
mance scale. All patients were evaluated with dual energy X-
ray absorptiometry (DEXA) test before the start of therapy.
Four mg zoledronic acid was administered intravenously
to each patient once a month in ﬁfteen minutes. Before
each administration serum creatinine and calcium levels
were determined routinely. All patients were given an
additional daily 500–1500mg oral dose calcium and 300–
900IU vitamin D during therapy.
During followup PSA, serum calcium, serum total
alkaline phosphates test were routinely studied every three
months.Theseraforbonemetabolicindicators(BALP,PINP,
and ICTP) were kept at −70◦C.
Patientsdidnothaveotherbonedisorders(osteomyelitis,
Paget’s disease, etc.) that might aﬀect serum levels of bone
metabolic indicators.
Levels of bone metabolic indicators before and after
therapy were determined.
Carboxyterminal pyridinoline cross-linked telopeptide
of type I collagen (ICTP) and aminoterminal propeptide
of type I procollagen (PINP) tests were studied using RIA
method (Orion Diagnostica, Espoo Finland). Reference in-
terval for ICTP and PINP was 2.1–5.0mg/L, 19–102µg/L,
respectively. Bone alkaline phosphates tests were studied
through RIA method (Tandem-R Ostase Beckman Coulter),
and reference interval was 5.50–17.50µg/L.
Statistical analyses were performed in SPSS 15 program
with Wilcoxon Signed Ranks Test. P<. 05 was accepted as
statistically signiﬁcant.
3.Result
Fifteen patients with hormone-resistant prostate cancer and
with bone metastases in their bone scintigraphy, whose ages
ranging 58–85 (median 73) were evaluated. Duration of the
followup was 2–15 months (median four months). External
radiotherapy for spinal cord compression symptoms devel-
opedduetovertebralmetastaseswasappliedtoeightpatients
(3000cGy).
Control tests were performed in the second month for
three patients and in the third month to others. Twelve
patients have been orchidectomised and three were under
androgen blockage (receptor blockage and LHRH agonists).
In the followup period, in ten patients PSA values were
100ng/ml and in the other ﬁve patients, PSA values were
tending to increase. But this increase did not reach statistical
signiﬁcance.
InDEXAtestsappliedbeforethetherapyallpatientswere
found to have decreased bone mineral density in lumbar
vertebrae and femur cervix (T score < −2.5, osteoporosis).
Although the zoledronic acid therapy patients were given
a daily 500–1500mg oral dose of calcium and 300–900IU
vitamin D signiﬁcant decrease in serum calcium levels after
the therapy was observed (Table 1).
When the patients TALP levels were compared, there
were statistically signiﬁcant decreases after therapy (P<. 01)
(Table 1).
Althoughtherewasadecreaseinotherboneconstruction
indicator BALP, this decrease (median before and after
therapy 29.40µg/L, resp.) was not statistically signiﬁcant
(P = .21) (Table 1).
When serum levels of bone destruction indicator ICTP
were compared, signiﬁcant decrease after zoledronic acid
therapy was determined (median before and after therapy
7.76µg/L and 5.65µg/L, resp.) (Table 1).
When performances of the patients were compared
a statistically signiﬁcant decrease in performances of the
patients due to the progression of the illness during the
therapy (P = .01) (Table 2) was observed. Six patients died
due to progression of the diseases during followup period.
All patients had bone pain in diﬀerent degrees assessed via
VAS caused by bone metastases. When pain before and after
therapywasassessed,signiﬁcant decreasesinpainscoreswere
determined(P = .01)(Table 2).Duetothisfactpatientsneed
for analgesics decreased.
In this study zoledronic acid was tolerated well. There
were no patientsgiving up therapy because ofadverse eﬀects.
Adverse eﬀects were mild to moderate in all of the patients
followed by the initial administration but the symptoms
disappeared within 24 hours without any need for additional
therapy. Adverseeﬀectswere nausea, myalgia, mild tremorin
hands, and fever not higher than 38◦C.
4.Comment
Although bone lesions seen in prostate cancer are of
osteoblastic characteristic, they make extreme bone con-
struction and destruction around metastatic areas [3]. Thus
both bone construction and destruction indicator levels in
serum become high.
BALP is localized in the plasma membrane of osteoblasts
and is released into circulation during bone mineralizationISRN Urology 3
Table 1: Comparison of bone metabolic indicators and serum
calcium levels in ﬁfteen patients before and after zoledronic acid
therapy.
Before therapy
median ± SE
(min-max)
After therapy
median ± SE
(min-max)
P
TALP 600.00 ± 167.48 294.00 ± 110.00 .01
IU/L (112.00–2390.00) (108.00–1422.00)
PINP 39.56 ± 84.29 35.73 ± 73.28 .33
µg/L (14.58–1000.00) (6–1000.00)
ICTP 7.76 ± 7.44 5.65 ± 5.13 .04
µg/L (2.89–93.11) (2.00–63.80)
BALP 29.40 ± 26.20 20.18 ± 38.10 .21
µG/L (7.63–319.73) (3.92–480)
Serum calcium 9.70 ± 0.15 9.0 ± 0.13 <.01
mg/dL (8.70–10.60) (8.20–9.80)
TALP: Total alkline phosphates, PINP: amino-terminal propeptide of type
I procollagen, ICTP: Carboxyterminal pyridinoline telopeptide of type I
collagen, BALP: bone speciﬁc alkaline phosphates.
Table 2: Comparison of pain scores of ﬁfteen patients before and
after therapy.
Before therapy
median ± SE
(min-max)
After therapy
median ± SE
(min-max)
P
Visual analogue 5.00 ± 0.41 1.00 ± 0.52 <.01
scale (VAS) (3.00–8.00) (0.00–6.00)
process [7]. It is an indicator of matrix maturation phase
[8]. BALP gives more speciﬁc information about bone
lesions than serum TALP. PINP is another bone construction
indicator. It shows constructions of collagen. It is indicator
of early or proliferation phase. ICTP is biochemical
indicator of bone destruction. It is product of collagen
destruction [7].
Androgen blockage have been a basic method in ad-
vanced prostate cancer for a long time, but it causes a
continuing decrease in bone mineral density during therapy.
183 patients receiving hormone therapy for advanced
prostate cancer was studied by Weston et al. bone mineral
density were measured at the 12th and 24th months of the
therapy. In the 12th month 36% of the patients and in the
24th month 62% of the patients had osteoporosis [9]. Risk
of bone fracture after androgen blockage therapy over ﬁve
years increased dramatically. This risk reaches around 50%
after a 9-year therapy [10].
Besides old age’s and androgen blockage therapy’s being
known risk factors for osteoporosis, prostate cancer is also
a cause for osteoporosis alone. Hussain and colleagues [11]
assessed 174 patients having newly diagnosed advanced
prostate cancer. Patients were evaluated with DEXA test
before any kind of therapy for prostate cancer. Results were
compared to a control group of 106 patients consisting of
people of similar ages not having prostate cancer but having
diﬀerent urological and medical illnesses. In patients having
advanced untreated prostate cancer there was a prominent
superabundance in osteoporosis in comparison to the
patients in the control group (42% in patients with prostate
cancer and 27% in the control group, P = .02). Although
age, smoking, and family background of osteop-orosis
increase the risk of osteoporosis, advanced prostate cancer
is an independent cause for osteoporosis alone. These
investigators suggest that bone mineral density be measured
routinely before androgen blockage therapy is started in
patients with advanced prostate cancer [11].
In another clinical study including 15 osteoporotic
patients in whom radical cystectomy had been performed,
both construction and destruction metabolic bone markers
increased signiﬁcantly following zoledronic acid treatment
(unpublished data).
Today palliative therapy for patients having malign
bone disorders consist of radiotherapy, chemotherapy, hor-
mone therapy, surgery, and intravenous bisphosphonates.
Randomized placebo controlled trials have indicated that
intravenous bisphosphonates decreases the frequency of
skeletalcomplicationswithmalign bonedisordersinpatients
with prostate cancer [12, 13].
Bone scintigraphy is frequently used in determining
the site and degree of bone metastases. However the use of
bone scintigraphy in the observation of the eﬃciency of the
therapy is limited. It is costly and time-consuming process.
It does not reﬂect the rapid skeletal response. Due to these
negotiations,intheobservationandeﬃciencydetermination
of the therapy, early skeletal response might be assessed via
biochemical bone metabolic indicators [14]. In a prospective
trial carried out by Schoenberger and colleagues [15], bone
metastases were found in 21 of 88 patients with malign
tumors. Inthese patientsbone scintigraphy was compared to
bone metabolic indicators. Sensitivity of bone scintigraphy
was 90%. The sensitivity and speciﬁcity of ICTP were 71%,
and 42%, and PINP 24% and 96%, respectively. Although,
bone scintigraphy is more expensive and time consuming
it is still the most sensitive technique especially in terms of
determining the site bone lesions and the frequency of bone
disorder [15].
In a trial carried out among postmenopausal women it
is determined that serum levels of bone construction and
destructionindicatorscausedbyosteoporosiswerehigh[16].
Similarly in this trial it was found that both bone
construction (TALP, BALP) and destruction (ICTP) indica-
tors for patients being under observation for 2–15 months
(median 4 month) were high. It was determined that there
was a statistically signiﬁcant decrease in serumlevelsof ICTP
after zoledronic acid therapy (P<. 05).
In this study numbers of the patients were low and the
observation period was short. Determining a signiﬁcant
decrease in serum levels of ICTP brought about the idea that
serial measurements of ICTP levels may be an important
guide in observation of zoledronic acid therapy; it is even
determined in early controls and it was preserved in late
controls and even decreased to normal serum levels in
patients being under the longest observation of 15 months.
Although there were decreases in serum levels of
bone construction indicators (BALP, PINP) they were not4 ISRN Urology
statistically signiﬁcant; these decreases in bone construction
indicators might be an indicator of decrease in abnor-
mal bone construction. Still bone construction indicators
decreasing less in proportion to the bone destruction indi-
cators may be due to respectively slowed down reactionary
new bone construction continuing with the inhibition
of osteoclasts by zoledronic acid. The decrease in bone
construction indicators when compared to the initial levels
although they were less aﬀected than destruction indicators,
and the signiﬁcant decrease in serum calcium levels may be
an indirect indicator of a better mineralization in the newly
constructed bone. In a study it was reported that zoledronic
acid therapy resulted in a 7.8% of increase in bone mineral
density [17].
Bone metastases are the most common reason for the
pain related to bones and sometimes require palliative
radiotherapy[18].Itwasreported thatbisphosphonateshave
an analgesic eﬀect on the pain in the bone in patients with
bone metastases [19].
In this trial eight patients received radiotherapy due to
ostalgia caused by vertebral involvement and spinal cord
compression symptoms. At the same time zoledronic acid
therapywascontinuedtobeapplied.Althoughperformances
of the patients decreased during observation due to pro-
gression in the illness there were signiﬁcant decreases in
pain scales. Additionally there was a decrease in patients’
needs for analgesics. There is limited information about
the optimal application period of zoledronic acid therapy
in the literature. Bone disorders caused by prostate cancer
are a serious life quality decreasing reason of morbidity.
Still, there is not a primary eﬃcient cure for bone disorders
caused by prostate cancer. Newly developed, intravenously
administered bisphosphonates are used with an increasing
rate in the palliative therapy of bone disorders. Location
and prevalence of the bone disorder and its response to the
therapy are assessed by techniques like bone scintigraphy
and DEXA which are expensive, time consuming, and not
good reﬂectors of early therapy response. Due to diﬃculties
in these techniques, serial measurement of serum levels of
bone metabolic indicators which can assess the diagnosis
and observation of the bone disorders caused by prostate
cancer and especially the early response to the therapy may
be useful. Therefore there is still a need for randomized trials
in larger series with patients of longer observation period.
Moreover it would increase the beneﬁt expected, to develop
m o r es e n s i t i v em o r es p e c i ﬁ cb o n ei n d i c a t o r s .
5.Conclusion
Zoledronic acid therapy decreased bone destruction and
was eﬀective in palliation of the pain in patient with bone
metastasis. Using bone metabolic indicators during the
followup of zoledronic acid therapy might be useful.
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